Histamine metabolites in cerebrospinal fluid of patients with chronic schizophrenia: their relationships to levels of other aminergic transmitters and ratings of symptoms
| Autor: | Charles A. Kaufmann, Markku Linnoila, Jack Peter Green, Darrell G. Kirch, George D. Prell, Albert M. Morrishow, Richard Jed Wyatt, Jai K. Khandelwal |
|---|---|
| Rok vydání: | 1995 |
| Předmět: |
Adult
Male Biogenic Amines Dyskinesia Drug-Induced Psychosis medicine.medical_specialty Tardive dyskinesia Norepinephrine (medication) Norepinephrine chemistry.chemical_compound Reference Values Internal medicine medicine Humans Biological Psychiatry Psychiatric Status Rating Scales Neurotransmitter Agents Methylhistamines Homovanillic acid Imidazoles Histaminergic Middle Aged medicine.disease Psychiatry and Mental health Endocrinology chemistry Dyskinesia Schizophrenia Chronic Disease Female Schizophrenic Psychology medicine.symptom Psychology Histamine Antipsychotic Agents medicine.drug |
| Zdroj: | Schizophrenia Research. 14:93-104 |
| ISSN: | 0920-9964 |
| DOI: | 10.1016/0920-9964(94)00034-6 |
| Popis: | Levels of the histamine metabolites, tele-methylhistamine (t-MH) and tele-methylimidazoleacetic acid (t-MIAA), and metabolites of other aminergic transmitters and of norepinephrine were measured in cerebrospinal fluid of 36 inpatients with chronic schizophrenia and eight controls. The mean t-MH level from controls was nearly identical to the levels seen previously in healthy volunteers. Compared with controls, the mean level of t-MH in the schizophrenic patients was 2.6-fold higher (p = 0.006); 21 of the patients had levels exceeding the range of controls. There was no significant difference (p > 0.05) in levels of other analytes, although the levels of t-MH correlated significantly with those of t-MIAA, homovanillic acid, 3,4-dihydroxyphenylacetic acid, norepinephrine, 3-methoxy-4-hydroxyphenylglycol and 5-hydroxyindoleacetic acid. The difference in levels of t-MH were not attributable to medication, since those taking (n = 10) or withdrawn from (n = 26) neuroleptic drugs had nearly the same mean levels of t-MH; each group had higher levels than controls (ANOVA: p < 0.05). Patients with or without tardive dyskinesia showed no significant differences in means of any analyte. Only levels of t-MH among those with schizophrenia correlated with positive symptom scores on the Psychiatric Symptom Assessment Scale (rs = 0.45, p < 0.02). The elevated levels of t-MH in cerebrospinal fluid, which represent histamine that was released and metabolized, suggest increased central histaminergic activity in patients with chronic schizophrenia. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect